Funding

[Funding alert] Mesenbio Secures £1.4Million in Funding

Jan 10, 2024 | By Startup Rise EU

Mesenbio secures £1.4million in funding. Together with grant funding from Innovate UK, DSW Ventures and NG Bio co-led the round.
Dr. David Kuntin-FOUNDER / CEO(left), Prof. Paul Genever- FOUNDER / CSO(right)

Mesenbio secures £1.4million in funding. Together with grant funding from Innovate UK, DSW Ventures and NG Bio co-led the round.

With the help of the funds, the company will be able to conduct pre-clinical research, build pilot manufacturing processes, hire three new employees, and get the regulatory dossier ready for clinical trials.

Read also - British Biotech FA Bio Raises €6.1 Million in Funding

Mesenbio, founded by Dr. David Kuntin and Professor Paul Genever, is developing an innovative therapy for arthritis made from modified human stem cells. The medicine is based on their work at the Biomedical Research Institute at the University of York.

RECOMMENDED FOR YOU

recomd
Recent Articles
Boosts Green Energy Solutions Danfoss Acquired ENFOR’s
Startup Rise EU
Jan 4, 2024
recomd
UK
[Funding alert] UK-based Known Leader in Property Technology iamproperty Secures Investment From Perwyn
Startup Rise EU
Oct 25, 2023
recomd
Funding
[Funding alert] Berlin-based Everphone Raises €270Million in Series D Round Funding
Startup Rise EU
Jan 17, 2024

The inflammatory illness that affects almost half a million people and children in the UK alone, rheumatoid arthritis, will be the primary focus of the treatment. It causes excruciating joint pain and inflammation in the hands, knees, elbows, ankles, and wrists.

Read also - Dutch AI Startup Whispp Secures €750k in Seed Funding

The therapy is based on nano-sized messengers made from human stem cells that have been developed to both reduce inflammation and stimulate the healing process of injured tissue.

About Mesenbio

A biopharmaceutical startup from the University of York, Mesenbio is in the preclinical stage. Their Cell Line Extracellular Vesicle Release (CLEVR) platform addresses the most common hurdle in extracellular vesicle therapeutics consistency, allowing us to pursue a diverse therapeutic pipeline. They utilise their platform to generate therapeutically stimulating extracellular vesicles in an infinitely dependable manner.

Read also - Lyon-based ENYO Pharma Secures a €39 Million in Series C Round Funding

Recommended Stories for You

story
Funding

[Funding alert] Madrid-based Car subscription service REVEL Raises €115 million in Funding

Startup Rise EU Sep 25, 2023

story
Germany

[Funding alert] Berlin-based HR Management Software Solutions Empion Secures €6M in Seed Funding

Startup Rise EU Oct 27, 2023

story
Funding

[Funding alert] Latiba-based Mapon Raises €3Million in Funding

Startup Rise EU Mar 12, 2024

story
Funding

[Funding alert] London-based NeoPhore Secures Additional £9.6Million in Series B Round Extension Funding

Startup Rise EU Feb 2, 2024

story
Funding

[Funding alert] Berlin-based Frontnow Secures €3.8 Million in Seed Funding

Startup Rise EU Mar 13, 2024

story
Funding

[Funding alert] Bern-based LEM Surgical Raises €23.6 Million in Series B Round Funding

Startup Rise EU Jan 5, 2024